Family Medicine Comprehensive Review Series

The discovery and development of immune checkpoint inhibitors has revolutionized the treatment of certain cancers, with the 2018 Nobel Prize in medicine/physiology recognizing these therapies as a "landmark in our fight against cancer." Yet, despite these advances, putative biomarker identification, efficacy, and drug resistance still pose significant therapeutic challenges. In this webinar, leaders in immuno-oncology — Elaine Mardis (The Ohio State University) and Jedd Wolchok (Memorial Sloan Kettering Cancer Center) — survey the landscape of research, revealing new approaches for harnessing the potential of this transformative therapeutic.

Everyone makes the best extracts. But are they optimized? And what does “the best” mean; does it mean high yield, high quality, or both? And what is quality anyway? Quality begins in the cultivation process and continues throughout the handling of the product from seed to sale. At OutCo, we’ve studied our production pipeline and extraction methodologies to offer optimized products to our patients. Finding the ideal balance between yield and consumer rating, we were able to optimize extraction protocols for controlled mixtures of compounds. Our custom methods enable us to create products with designer cannabinoid and terpene ratios, customized to patients’ and doctors’ needs. All of this was achieved in an efficient manner through the use of design of experiment (DoE) techniques, and continuous improvement of all processes.

After watching this webinar, participants will be familiar with: basic settings and parameters of pacemakers; how to integrate and program pacemakers; and how to identify common pacemaker-related issues.

Implementation of biobanking best practices and analytical platform standardization are two important components for any data generation associated with state of the art biobanks that support precision medicine applications. Sample collection, pre analytical variables, controlled environment storage and sample processing can often have a large impact on the quality of biomaterials. This roundtable will describe how to standardize biobanking efforts in a manner commensurate with both academic and industrial partnerships. Data will be presented on the governance of biosample collections, standardization efforts, and quality control harmonization for biosamples as well as global best practices for the regulatory oversight of national and commercial biobank resources. Finally, a review of several international programs will illustrate how collaborative efforts are helping advance integrated biobanking precision medicine across many research and clinical areas.